Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors

Abstract

Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiological JAK2 signalling. We tested whether combining a JAK2 inhibitor with a series of serine threonine kinase inhibitors, targeting nine signalling pathways and already used in clinical… (More)
DOI: 10.1111/jcmm.12156

6 Figures and Tables

Topics

Statistics

050100150201320142015201620172018
Citations per Year

214 Citations

Semantic Scholar estimates that this publication has 214 citations based on the available data.

See our FAQ for additional information.

  • Presentations referencing similar topics